Tags

Type your tag names separated by a space and hit enter

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease.

Abstract

BACKGROUND

Coadministration of mometasone furoate (MF) and formoterol fumarate (F) produces additive effects for improving symptoms and lung function and reduces exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). The present study assessed the relative systemic exposure to MF and characterized the pharmacokinetics of MF and formoterol in patients with COPD.

METHODS

This was a single-center, randomized, open-label, multiple-dose, three-period, three-treatment crossover study. The following three treatments were self-administered by patients (n = 14) with moderate-to-severe COPD: MF 400 μg/F 10 μg via a metered-dose inhaler (MF/F MDI; DULERA(®)/ZENHALE(®)) without a spacer device, MF/F MDI with a spacer, or MF 400 μg via a dry-powder inhaler (DPI; ASMANEX(®) TWISTHALER(®)) twice daily for 5 days. Plasma samples for MF and formoterol assay were obtained predose and at prespecified time points after the last (morning) dose on day 5 of each period of the crossover. The geometric mean ratio (GMR) as a percent and the corresponding 90% confidence intervals (CI) were calculated for treatment comparisons.

RESULTS

Systemic MF exposure was lower (GMR 77%; 90% CI 58, 102) following administration by MF/F MDI compared to MF DPI. Additionally, least squares geometric mean systemic exposures of MF and formoterol were lower (GMR 72%; 90% CI 61, 84) and (GMR 62%; 90% CI 52, 74), respectively, following administration by MF/F MDI in conjunction with a spacer compared to MF/F MDI without a spacer. MF/F MDI had a similar adverse experience profile as that seen with MF DPI. All adverse experiences were either mild or moderate in severity; no serious adverse experience was reported.

CONCLUSION

Systemic MF exposures were lower following administration by MF/F MDI compared with MF DPI. Additionally, systemic MF and formoterol exposures were lower following administration by MF/F MDI with a spacer versus without a spacer. The magnitude of these differences with respect to systemic exposure was not clinically relevant.

Authors+Show Affiliations

Clinical Pharmacology, Merck Sharp & Dohme Corp, Whitehouse Station, NJ, USA. teddy.kosoglou2@merck.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23525511

Citation

Kosoglou, Teddy, et al. "Comparison of the Systemic Bioavailability of Mometasone Furoate After Oral Inhalation From a Mometasone Furoate/formoterol Fumarate Metered-dose Inhaler Versus a Mometasone Furoate Dry-powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease." International Journal of Chronic Obstructive Pulmonary Disease, vol. 8, 2013, pp. 107-16.
Kosoglou T, Hubbell J, Xuan F, et al. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:107-16.
Kosoglou, T., Hubbell, J., Xuan, F., Cutler, D. L., Meehan, A. G., Kantesaria, B., & Wittmer, B. A. (2013). Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease, 8, pp. 107-16. doi:10.2147/COPD.S36592.
Kosoglou T, et al. Comparison of the Systemic Bioavailability of Mometasone Furoate After Oral Inhalation From a Mometasone Furoate/formoterol Fumarate Metered-dose Inhaler Versus a Mometasone Furoate Dry-powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2013;8:107-16. PubMed PMID: 23525511.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease. AU - Kosoglou,Teddy, AU - Hubbell,James, AU - Xuan,Fengjuan, AU - Cutler,David L, AU - Meehan,Alan G, AU - Kantesaria,Bhavna, AU - Wittmer,Bret A, Y1 - 2013/03/04/ PY - 2013/3/26/entrez PY - 2013/3/26/pubmed PY - 2013/6/15/medline KW - chronic obstructive pulmonary disease KW - dry-powder inhaler KW - metered-dose inhaler KW - mometasone furoate KW - pharmacokinetics KW - systemic exposure SP - 107 EP - 16 JF - International journal of chronic obstructive pulmonary disease JO - Int J Chron Obstruct Pulmon Dis VL - 8 N2 - BACKGROUND: Coadministration of mometasone furoate (MF) and formoterol fumarate (F) produces additive effects for improving symptoms and lung function and reduces exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). The present study assessed the relative systemic exposure to MF and characterized the pharmacokinetics of MF and formoterol in patients with COPD. METHODS: This was a single-center, randomized, open-label, multiple-dose, three-period, three-treatment crossover study. The following three treatments were self-administered by patients (n = 14) with moderate-to-severe COPD: MF 400 μg/F 10 μg via a metered-dose inhaler (MF/F MDI; DULERA(®)/ZENHALE(®)) without a spacer device, MF/F MDI with a spacer, or MF 400 μg via a dry-powder inhaler (DPI; ASMANEX(®) TWISTHALER(®)) twice daily for 5 days. Plasma samples for MF and formoterol assay were obtained predose and at prespecified time points after the last (morning) dose on day 5 of each period of the crossover. The geometric mean ratio (GMR) as a percent and the corresponding 90% confidence intervals (CI) were calculated for treatment comparisons. RESULTS: Systemic MF exposure was lower (GMR 77%; 90% CI 58, 102) following administration by MF/F MDI compared to MF DPI. Additionally, least squares geometric mean systemic exposures of MF and formoterol were lower (GMR 72%; 90% CI 61, 84) and (GMR 62%; 90% CI 52, 74), respectively, following administration by MF/F MDI in conjunction with a spacer compared to MF/F MDI without a spacer. MF/F MDI had a similar adverse experience profile as that seen with MF DPI. All adverse experiences were either mild or moderate in severity; no serious adverse experience was reported. CONCLUSION: Systemic MF exposures were lower following administration by MF/F MDI compared with MF DPI. Additionally, systemic MF and formoterol exposures were lower following administration by MF/F MDI with a spacer versus without a spacer. The magnitude of these differences with respect to systemic exposure was not clinically relevant. SN - 1178-2005 UR - https://www.unboundmedicine.com/medline/citation/23525511/Comparison_of_the_systemic_bioavailability_of_mometasone_furoate_after_oral_inhalation_from_a_mometasone_furoate/formoterol_fumarate_metered_dose_inhaler_versus_a_mometasone_furoate_dry_powder_inhaler_in_patients_with_chronic_obstructive_pulmonary_disease_ L2 - https://dx.doi.org/10.2147/COPD.S36592 DB - PRIME DP - Unbound Medicine ER -